Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Barr: Emergency contraceptive Plan B second quarter sales increased $12 mil. over the year-ago quarter due to the OTC launch in November 2006, Barr reports in an Aug. 8 analysts call ("1The Tan Sheet" March 5, 2007, In Brief and 2"The Tan Sheet" Nov. 13 2006, p. 8). The firm's total revenues for the quarter were $637 mil., up 81% from the same period in the prior year. With Plan B boosting its proprietary division sales, generic oral contraception sales also drove overall revenue. Integration of Croatian firm PLIVA acquired in 2006 is on track, the firm reports...
You may also be interested in...
Texas AG Files Suit Alleging Mannatech Uses False Claims In Marketing
Texas Attorney General Greg Abbott has filed a lawsuit seeking to shut down Mannatech, but the firm's executives advise their multi-level marketing associates to continue conducting business as usual, predicting a "marathon" in defending the suit
Plan B launches “strong”
Barr Pharmaceuticals says "strong sales" of Plan B emergency contraceptive following its November launch contributed to a 22% increase in sales of the firm's proprietary products during its fiscal 2007 second quarter. In a Feb. 28 earnings call, the company said proprietary product sales for the October-December period increased $17 million from the year-ago period to $98 million. The firm declined to provide Plan B sales details, but Chairman and CEO Bruce Downey said the product "is up substantially ... year over year as a result of the OTC switch." Downey said Barr's three-year exclusivity for Plan B began with its launch, but the firm is "evaluating the options that we have for protecting that franchise beyond" its patents (1"The Tan Sheet," Nov. 13, 2006, p. 8)...
Dual Package Plan B Hits Shelves Mid-November With Three-Year Exclusivity
The first product to be approved in a single package for both Rx and OTC sale - Barr Pharmaceuticals' emergency contraceptive Plan B - will be available behind pharmacy counters by mid-November, according to the firm